LYSOGENE overview

Regulatory News: Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that the Commercial Court of Nanterre has decided to convert the reorganization proceedings of the Company, opened by judgment on January 24, 2023, into liquidation proceedings. As a result, trading of Lysogene’s shares will not resume and a delisting will be requested from Euronext soon. About Lysogene Lysogene is a gene therapy Company focused...

Regulatory News: Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that on May 23, 2023, the Commercial Court of Nanterre will hold a hearing to decide on the outcome of the Company's reorganization proceedings and on the possible opening of judicial liquidation proceedings. In the event of the opening of judicial liquidation proceedings, the Company will send a delisting request to Euronext. In this context, the...

Regulatory News: Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that it will not be able to release its 2022 financial results and its 2022 Universal Registration Document before the April 30, 2023 deadline. The Commercial Court of Nanterre should rule on the next steps regarding the reorganization proceedings and on the possible opening of a judicial liquidation proceedings in the coming weeks. In this context,...

Regulatory News: Lysogene (FR0013233475 – LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that no takeover offer was filed before the deadline of April 12, 2023. As a reminder, the search for buyers was part of the ongoing reorganization proceedings opened by decision of the Commercial Court of Nanterre on January 24, 2023. The Commercial Court of Nanterre should rule on the next steps regarding the reorganization proceedings and on the...

Regulatory News: Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that, upon decision of the judicial administrator, the deadline for submitting offers has been extended from March 15, 2023 to April 12, 2023 at 12:00 (noon). Interested candidates are invited to contact: SELARL FHB, Administrateurs Judiciaires Associés Me Helene BOURBOULOUX, 176, avenue Charles de Gaulle 92200 Neuilly-sur-Seine e-mails...

Regulatory News: Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that, upon decision of the judicial administrator, the deadline for submitting offers has been extended from February 15, 2023 to March 15, 2023 at 12:00 (noon). Interested candidates are invited to contact: SELARL FHB, Administrateurs Judiciaires Associés Me Helene BOURBOULOUX, 176, avenue Charles de Gaulle 92200 Neuilly-sur-Seine...